comparemela.com
Home
Live Updates
Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Gastric or Gastroesophageal Junction Adenocarcinoma : comparemela.com
Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Gastric or Gastroesophageal Junction Adenocarcinoma
Agilent Technologies, Inc. announced that it has received FDA approval for the use of PD-L1 IHC 22C3 pharmDx as a diagnostic tool to aid in identifying patients with Gastric or Gastroesophageal...
Related Keywords
,
Agilent Technologies Inc
,
Agilent Technologies
,
Gastroesophageal Junction
,
Markets
,
comparemela.com © 2020. All Rights Reserved.